Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SALVO
- 31 Mar 2023 Results published in the Clinical Cancer Research
- 01 Aug 2022 Planned End Date changed from 1 Apr 2023 to 1 Sep 2023.
- 01 Aug 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Sep 2022.